Clinical Trial Update: Vancomycin Taper to Prevent Recurrent Clostridioides Difficile [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a vancomycin taper strategy to prevent recurrent Clostridioides difficile infection; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Vancomycin (vancomycin)

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Clostridia Difficile Colitis | Phase 3 | Status: NOT_YET_RECRUITING